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Abstract
Background: Topical microbicides, used by women to prevent the transmission of HIV and other sexually transmitted
infections are urgently required. Dendrimers are highly branched nanoparticles being developed as microbicides. However,
the anti-HIV and HSV structure-activity relationship of dendrimers comprising benzyhydryl amide cores and lysine branches,
and a comprehensive analysis of their broad-spectrum anti-HIV activity and mechanism of action have not been published.
Methods and Findings: Dendrimers with optimized activity against HIV-1 and HSV-2 were identified with respect to the
number of lysine branches (generations) and surface groups. Antiviral activity was determined in cell culture assays. Time-
of-addition assays were performed to determine dendrimer mechanism of action. In vivo toxicity and HSV-2 inhibitory
activity were evaluated in the mouse HSV-2 susceptibility model. Surface groups imparting the most potent inhibitory
activity against HIV-1 and HSV-2 were naphthalene disulfonic acid (DNAA) and 3,5-disulfobenzoic acid exhibiting the
greatest anionic charge and hydrophobicity of the seven surface groups tested. Their anti-HIV-1 activity did not appreciably
increase beyond a second-generation dendrimer while dendrimers larger than two generations were required for potent
anti-HSV-2 activity. Second (SPL7115) and fourth generation (SPL7013) DNAA dendrimers demonstrated broad-spectrum
anti-HIV activity. However, SPL7013 was more active against HSV and blocking HIV-1 envelope mediated cell-to-cell fusion.
SPL7013 and SPL7115 inhibited viral entry with similar potency against CXCR4-(X4) and CCR5-using (R5) HIV-1 strains.
SPL7013 was not toxic and provided at least 12 h protection against HSV-2 in the mouse vagina.
Conclusions: Dendrimers can be engineered with optimized potency against HIV and HSV representing a unique platform
for the controlled synthesis of chemically defined multivalent agents as viral entry inhibitors. SPL7013 is formulated as
VivaGelH and is currently in clinical development to provide protection against HIV and HSV. SPL7013 could also be
combined with other microbicides.
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Introduction
UNAIDS (2007) estimates that 33.2 million people are infected
with human immunodeficiency virus (HIV) and half of these are
women [1]. While male condoms and male circumcision have
demonstrated efficacy in preventing HIV infection, negotiating the
use of condoms can be difficult for women and circumcision does
not directly prevent male to female HIV transmission [2,3].
Accordingly, microbicides are being developed that prevent or
reduce transmission of HIV and other sexually transmitted
PLoS ONE | www.plosone.org 1 August 2010 | Volume 5 | Issue 8 | e12309infections (STIs) when applied to the vagina or rectum [4].
Microbicide classes include nonspecific surfactants or detergents
and acid buffering agents, moderately specific macromolecular
anionic polymers that block HIV and other STIs, and HIV
specific drugs that inhibit viral entry and reverse transcription [4].
We have been focused on the discovery and development of
microbicides with broad-spectrum antiviral activity as there is a
demonstrated correlation between herpes simplex type 2 (HSV-2)
incidence and increased risk of HIV acquisition [5,6]. Thus
microbicides that block both HIV and HSV can potentially reduce
HIV transmission either directly or indirectly by preventing HSV
acquisition.
Recognised as a key building block of nanotechnology, dendri-
mers (dendri-=tree, -mer=branching) are a relatively new class of
macromolecule characterised by highly branched, well-defined,
three-dimensional structures that are being developed as drug
delivery vehicles and as therapeutic agents [7,8]. The controlled
synthesis of dendrimers allows the assembly of highly defined, single
molecule structures that radiate out in branches from a central
initiator core (Figure 1A). The type of core and branching units
(Figure 1B) can be altered to generate dendrimers of varying size
and shape. In addition, dendrimer branches can be capped with
different surface groups (Figure 1C) that can impart distinct
biological and pharmacological properties. Thus dendrimers offer
unique opportunities in the synthesis of agents with broad-spectrum
antiviral activity [9]. Viruses rely on interactions with host receptors
for binding and entry into target cells. Unlike small molecule drugs
that tend to make monovalent contacts, dendrimers can bind to
their target in a multivalent manner and overcome intrinsically
weak monovalent interactions thus representing an attractive
strategy for the development of viral entry inhibitors.
In this study we determined the structure-activity relationship
(SAR) of dendrimers with regard to HIV-1 and HSV-2 inhibitory
activity.WefocusedondendrimerswithL-lysinebranchesthathave
the dual advantage of greater stability and the capacity for synthesis
as a pure species compared to previously reported approaches using
polyamidoamine (PAMAM) linkages [10,11]. Dendrimers were
synthesized with 1 to 5 L-lysine branches (generations) and capped
with one of seven different surface groups. The most potent
dendrimers were selected for further evaluation in in vitro and in vivo
studies and their mechanism of action was elucidated. Our SAR
studies demonstrate that the dendrimer with the best overall profile
with regard to potent dual action antiviral activity and potential to
block cell-to-cell transmission of HIV was SPL7013, a fourth
generation (G4) dendrimer with napththalene disulfonic acid
(DNAA) surface groups. In contrast to linear polyanions,
SPL7013 has similar potency against CCR5-(R5) and CXCR4-
(X4) using strains of HIV-1. This dendrimer is the active
pharmaceutical ingredient in VivaGelH currently in clinical
development as a topical microbicide.
Results
Synthesis and purification of L-lysine dendrimers
Lysine dendrimers were prepared from a core comprising the
benzhydryl amide of (L)-lysine using iterative cycles of Boc
deprotection as described previously [12,13]. All Boc-protected
lysine dendrimers from generations one to five were chemically
and physically stable and were prepared for subsequent surface
functionalisation. This process involved Boc deprotection and
formation of a carboxylic acid amide bond with one of seven
possible surface capping groups: 4-sulfobenzoic acids sodium salt
(4-Ph-SO3Na), L-glutamic acid (glutamic), 1,3,5-benzenetricar-
boxylic acid [3,5-Ph-(CO2Na)2], 3-sulfo-thiophene-2-carboxylic
acid (2-thio-3-SO3Na), 3,5-disulfobenzoic acid sodium salt [3,5-
Ph-(SO3Na)2], 2-[(3,6-disulfo-1-naphthalenyl)oxy]acetic acid diso-
dium salt (DNAA) and 2-[(3-monosulfo-1-naphthalenyl)oxy]acetic
acid sodium salt (MNAA). All dendrimers used in this study were
.95% pure by HPLC and characterised by a variety of additional
analytical techniques.
HIV-1 inhibitory SAR studies with L-lysine dendrimers
The anti-HIV-1 SAR of L-lysine dendrimers was determined
with respect to the number of generations and the surface groups
(Figure 1C). Surface groups were examined with respect to anionic
diversity (i.e. sulfonic acid or carboxylic acid) and lipophilic
modifications (i.e. phenyl, naphthalene or alkyl). Dendrimers were
evaluated for their capacity to inhibit replication of NL4.3, a HIV-
1 strain that utilizes the chemokine coreceptor CXCR4 (X4 strain)
for entry, in MT-2 cells. A positive control for HIV-1 inhibition
was included in each assay to validate assay performance. The
cytotoxicity of dendrimers was evaluated in the same assays.
The smallest dendrimers with potent anti-HIV-1 activity
(defined as dendrimers with 50% effective concentration (EC50)
values in the submicromolar range) were G2 dendrimers capped
with DNAA or 3,5-Ph-(SO3Na)2, the former being more potent
(Figure 1D and Table S1). In contrast, 3,5-Ph-(CO2Na)2 or 4-Ph-
SO3Na surface groups conferred sub-micromolar inhibition of
HIV-1 only when appended to G3 or larger dendrimers. Potent
anti-HIV activity was observed for the MNAA surface group on a
G4 dendrimer. The 2-thio-3-SO3Na and glutamic surface groups
did not yield potent dendrimers. The selectivity index (SI) of the
dendrimers was calculated to determine the specificity of HIV-1
inhibition at noncytotoxic concentrations (Figure S1). The G2
DNAA dendrimer had the greatest SI (SI=940), while 3,5-Ph-
(SO3Na)2 yielded the second most active G2 dendrimer (SI=196)
in MT-2 cells. These data demonstrate that dendrimers capped
with a surface group imparting the greatest hydrophobicity
and anionic charge density (i.e. DNAA, Figure 1C) were the most
active particularly in the context of a smaller dendrimer. In
addition, aryl sulfonic and carboxylic acid surface groups
conferred the most potent HIV-1 inhibitory activity.
HSV-2 inhibitory SAR studies with L-lysine dendrimers
We evaluated the HSV-2 inhibitory SAR of dendrimers
focusing on surface groups that impart different degrees of
hydrophobicity (i.e. phenyl vs naphthalene) and anionic density
(i.e. one vs two sulfonic acid residues). HSV-2 inhibitory activity
was determined in human embryonic lung (HEL) cells infected
with the wild-type HSV-2 clinical isolate 250733 [14]. Dendrimer
concentrations tested were not cytotoxic to HEL cells. Comparison
of the HSV-2 inhibitory activity of G3 dendrimers capped with
DNAA, 3,5-Ph-(SO3Na)2 and 4-Ph-SO3Na revealed that DNAA
(EC50 6 standard error, 0.1260.02 mM) and 3,5-Ph-(SO3Na)2
(0.2660.08 mM, n=3, p=0.2) capped dendrimers demonstrated
similar potency while dendrimers capped with 4-Ph-SO3Na
(19.364.8 mM, n=3, p=0.05) was 160-fold less potent than
DNAA capped dendrimers (Figure 1E). These data demonstrate
that DNAA and 3,5-Ph-(SO3Na)2, the surface groups with the
greatest hydrophobicity and negative charge density, were the
most active against HSV-2.
Evaluation of G2–G5 dendrimers in the DNAA series revealed
that anti-HSV-2 potency increased as dendrimers became larger,
with the G5 dendrimer demonstrating the greatest potency
(0.0360.003 mM) (Figure 1E). This is in contrast to the anti-
HIV-1 activity of the DNAA series where potency did not increase
beyond G2 (Figure 1D). A similar relationship between increased
dendrimer size and potency was also observed for inhibition of
Dendrimer Antiviral Activity
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dendrimer EC50 was 93-fold lower (0.1360.03 mM, n=10) than
the G2 DNAA dendrimer (12.361.9 mM, n=4, p,0.007). A
similar pattern was also observed for the laboratory strains HSV-
1(F) and HSV-2(G) (data not shown). Taken together these data
demonstrate that there is a distinct difference in the HIV-1 and
HSV-2 inhibitory SAR of dendrimers, and that they can be
engineered with optimized potency for HIV-1 and HSV-2.
Broad-spectrum anti-HIV activity of SPL7013 and
SPL7115
HIV entry is initiated by binding of the gp120 surface
glycoprotein to the CD4 receptor on the host cell which leads
to conformational changes in gp120 and subsequent binding to
the host cell CXCR4 or CCR5 chemokine coreceptors [15].
Interactions of gp120 with either CXCR4 or CCR5 drive
conformational changes in the gp41 transmembrane glycoprotein
resulting in fusion of viral and cellular membranes and viral entry.
Sexual transmission of HIV is normally mediated by strains that
utilize the CCR5 chemokine receptor [16]. Accordingly, we
determined the inhibitory activity of dendrimers that were
amongst the most potent inhibitors against NL4.3 in the SAR
study (Figure 1D) for their inhibitory activity against the CCR5-
using (R5) strain, HIVBa-L, compared to NL4.3 in the TZM-bl cell
line (Table S1). Of the six dendrimers tested, G2 (SPL7115) and
G4 (SPL7013) dendrimers capped with DNAA were the most
potent in inhibiting NL4.3 while SPL7013 was the most potent
against HIVBa-L (Table S1). We selected SPL7013 (Figure 2A) and
SPL7115 (Figure 2B) for further evaluation to compare the activity
of a smaller G2 and a larger G4 dendrimer.
We investigated the ability of SPL7013 and SPL7115 to inhibit
different HIV-1 clades circulating worldwide. Both dendrimers
inhibited all HIV-1 clades (A, B, C, D, EA, F, G and O) and HIV-2
strainstested(Table1andTablesS2,S3andS4).However,withthe
exception of NL4.3, where the activities of the dendrimers were
similar, SPL7013 was 1.1–6.4-fold more potent in inhibiting HIV-1
compared to SPL7115 (Table 1) and demonstrated sub-micromolar
inhibition for all strains tested (Table 1, Tables S2, S3 and S4).
SPL7013 also showed similar inhibitory activity against both early
circulating (NB25 and NB27) and late emerging (NB2 and NB6) R5
strains isolated from the peripheral blood mononuclear cells
(PBMC) of HIV-1 infected individuals [17]. These data demon-
strate that SPL7013 has broad-spectrum anti-HIV activity as
demonstrated in both a cell line and in human PBMCs.
Linear polyanions are generally more potent at inhibiting X4
compared to R5 strains of HIV-1 due to interaction of the
polyanion with the highly charged V3 loop on X4 strains [18,19].
The lower potency of linear polyanions against R5 strains has been
suggested as one explanation for their inability to prevent HIV
acquisition in clinical trials [20,21,22]. Dendrimers are structurally
and chemically distinct from linear polyanions, harboring a unique
DNAA surface group. Accordingly, we determined whether
SPL7013 and SPL7115 were more potent in inhibiting X4
compared to R5 HIV-1 strains (Table 1). We found no signi-
ficant difference between the mean SPL7013 EC50 for X4
(0.1460.04 mM, n=4) and R5 (0.1360.02 mM, n=10, p=0.07)
strains. No significant difference was also observed for the mean
SPL7115 EC50 values for X4 (0.4760.18 mM, n=4) and R5
(0.5760.10 mM, n=10, p=0.14) strains. Since the presence of the
cationic polymer DEAE-Dextran used to enhance HIV-1 infection
in TZM-bl cells may differentially affect the dendrimer EC50
values for X4 and R5 strains [23], we also examined SPL7013
inhibition of HIV-1 from different clades in phytohemagglutinin
(PHA) stimulated human PBMCs (Table S2). Similar to the TZM-
bl data we observed no significant difference between the mean
SPL7013 EC50 for X4 (0.1260.03 mM, range 0.05–0.17, n=4)
and R5 (0.0960.05 mM, range 0.02–0.15, n=7, p=0.18) strains.
These data show that in contrast to polyanion polymers [18,19],
SPL7013 demonstrates similar potency in the inhibition of X4 and
R5 strains of HIV-1.
We also evaluated the effects of human serum and human
cervicovaginal secretions (CVS) on the HIV-1 inhibitory activity of
SPL7013 in viral infectivity assays (Figure S2). In the presence of
40% human serum there was less than a 2-fold increase in the
SPL7013 EC50 value compared to cultures infected in medium
containing no human serum (Figure S2A). In addition, pooled
human CVS had little impact on the SPL7013 EC50 with ,3-fold
increase compared to no CVS (Figure S2B). These data indicate
that high protein or CVS is unlikely to have a major impact on the
ability of SPL7013 to inhibit HIV-1 infection in vivo.
Formulated SPL7013 (VivaGelH) demonstrates prolonged
in vivo protection against HSV-2 in the mouse vaginal
transmission model and does not cause toxicity that
increases susceptibility to HSV-2
Previous studies have demonstrated that SPL7013 blocks HSV-2
infection in the mouse. However, these studies did not examine the
longevity of the protection [24], which has impli-
cations with regard to how long before coitus the micro-
bicide can be applied. Therefore we tested the ability of formulated
SPL7013, VivaGelH (3% w/w SPL7013 in Carbopol gel at pH 4.5),
to provide extended protection against vaginal transmission of
HSV-2 in the mouse. VivaGelH provided prolonged protection
lasting at least 12 h, and gave complete protection for more than
1 h (p=0.01 at 12 h; p,0.001 at shorter times)(Figure 3A). These
data are consistent with and extend a previous study demonstrating
that formulated SPL7013 protects against vaginal HSV-2 infection
when applied up to 60 min before viral challenge in the mouse [24].
Topical microbicides should not cause toxic effects that increase
susceptibility to infections [16]. Mouse HSV-2 susceptibility
models can detect any toxic effect, regardless of mechanism, that
increases susceptibility to HSV-2 infection [25,26]. In this model
the animals are pretreated with Depo-Provera to expose living
cells on the entire surface of the vagina making the mouse vagina
more closely mimic the most accessible HSV-2 target cells in the
Figure 1. Dendrimer structure and SAR of L-lysine dendrimers against HIV-1 and HSV-2. (A). Model representation of dendrimer structure
showing central core, branches in black, red and green for first (G1), second (G2) and third (G3) generations and surface groups denoted as blue
round spheres. (B). Different types of cores and branches used in the synthesis of dendrimers. (C). Seven surface groups, L-glutamic acid, 2-thio-3-
SO3Na, MNAA, 4-Ph-SO3Na, 3,5-Ph-(SO3Na)2, DNAA and 3,5-Ph-(CO2Na)2 evaluated in SAR studies. (D). SAR of L-lysine dendrimers against HIV-1 strain
NL4.3 performed in MT-2 cells. G1–G5 dendrimers were evaluated for five of the seven surface groups except for MNAA where G1-G2 and G5 were
not tested and 2-thio-3-SO3Na where G1 and G5 dendrimers were not tested. The EC50 values were obtained from at least two independent assays
except for G1–G5 dendrimers with the glutamic surface group, G1 dendrimers with the 2-thio-3-SO3Na, 3,5-Ph(SO3Na)2, DNAA and 3,5-Ph-(CO2Na)2
surface groups and the G3 MNAA dendrimer, where one assay was performed. (E). SAR of L-lysine dendrimers against HSV-2 performed in HEL cells.
G4-G5 and G2, G4-G5 were not tested for dendrimers with the 3,5-Ph-(SO3Na)2 and 4-Ph-SO3Na surface groups, respectively. EC50 values were
obtained from at least three independent assays. Error bars denote standard error of the mean.
doi:10.1371/journal.pone.0012309.g001
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of the endocervical canal and regions of cervical ectopy that occur
commonly in younger women, regions in which living cells are
exposed directly on the face of the cervix. Mice exposed to a single
dose of nonoxynol 9 and every other detergent-based candidate so
far tested provide at most a few minutes of protection followed by
several hours in which their susceptibility is greatly increased [25]
(Figure 3B). In contrast, animals exposed to a single application of
VivaGelH or the universal hydroxyethylcellulose (HEC) placebo
gel did not demonstrate increased susceptibility to HSV-2
infection. These data are consistent with the lack of disruption
of tight junctions between polarized epithelial cells by SPL7013
in vitro [27] and indicate that VivaGelH does not disrupt the mouse
vaginal epithelium.
Mechanism of HIV-1 inhibition by SPL7013 and SPL7115
While SPL7013 and SPL7115 are anticipated to inhibit HIV-1
infection by preventing viral entry, the dendrimer SPL2923
(BRI2923), which comprises an ammonia core, four generations of
PAMAM branches and 24 DNAA surface groups, inhibits not only
HIV-1 entry but also recombinant HIV-1 reverse transcriptase
(RT) and reverse transcription in HIV-1 infected cells [11].
Accordingly, we investigated whether SPL7013 and SPL7115
inhibit recombinant HIV-1 RT activity (Figure 4A). The SPL7013
50% inhibitory concentration (IC50 6 standard error)
(0.6960.04 mg/ml) was similar to SPL2923 (0.4860.05 mg/ml)
while SPL7115 was less active (17.960.04 mg/ml). These data
demonstrate that lysine-based DNAA dendrimers can also inhibit
recombinant HIV-1 RT.
To determine whether SPL7013 and SPL7115 inhibit HIV-1
reverse transcription in HIV-1 infected cells we performed a time
of addition assay in the TZM-bl indicator cell line (Figure 4B). The
experiments included the controls AMD3100, a CXCR4 antag-
onist that blocks HIV-1 entry, and nevirapine, a nonnucleoside
reverse transcriptase inhibitor (NNRTI). As expected, the addition
of nevirapine could be delayed for up to 6 h post infection before
loss of its HIV-1 inhibitory activity while AMD3100 failed to block
HIV-1 replication if the drug was added after virus addition
(Figure 4B). Both concentrations of SPL7013 and SPL7115
behaved similarly to AMD3100 indicating that they inhibit viral
entry but not reverse transcription in TZM-bl cells, presumably
because they either fail to enter cells or they cannot access RT
within the reverse transcription complex. These data demonstrate
that both SPL7013 and SPL7115 inhibit HIV-1 entry.
SPL7013 and SPL7115 block R5 and X4 envelope
mediated cell-to-cell fusion
We examined the relative ability of dendrimers to inhibit X4
versus R5 envelope mediated cell-to-cell fusion to gain insights into
dendrimer properties required for potent inhibition of cell-
associated HIV-1 transmission. SPL7013 inhibited both X4 and
R5 envelope mediated fusion with 50% fusion concentrations (FC50
6 standard error) of 0.0860.02 mM (n=3) and 0.9460.19 mM
(n=4), respectively (Figure 4C). In contrast, SPL7115 was 4.4-fold
Figure 2. Chemical structure of SPL7013 and SPL7115. (A) Structure of G4 L-lysine dendrimer with DNAA surface groups and formula weight
16,582. (B) Structure of G2 L-lysine dendrimer with DNAA surface groups and formula weight 4,187.
doi:10.1371/journal.pone.0012309.g002
Table 1. SPL7013 and SPL7115 have broad-spectrum activity against HIV-1 strains and HIV-2 as determined in TZM-bl cells.
HIV Strain Clade Co-receptor usage
a Mean SPL7013 EC50 (mM)
b Mean SPL7115 EC50 (mM)
b
NL4.3 B X4 0.2060.04 0.1860.05
Ba-L B R5 0.2660.05 1.0860.28
92RW016 A R5 0.1460.06 0.6560.31
92BR025 C R5 0.0760.01 0.4560.07
92UG046 D X4 0.2260.08 0.9960.49
CMU02 EA X4 0.1060.04 0.4560.04
93BR020 F Dual tropic 0.1160.02 0.4860.11
BCF01 O R5 0.1560.02 0.6060.09
CB1-br B X4 0.0560.02 0.2760.07
MACS1-spln B Dual tropic 0.0760.02 0.0860.05
MACS3-LN B R5 0.0860.02 0.4560.12
MACS3-br B R5 0.0960.03 0.5160.19
NB2
c B R5 0.1960.05 0.6660.10
NB6
c B R5 0.0960.01 0.3260.02
NB25
f B R5 0.1060.01 0.5360.16
NB27
f B R5 0.1060.01 0.4760.02
HIV-2 X4 0.0960.004 0.3860.07
aX4 denotes HIV that uses the CXCR4 chemokine receptor for entry, R5 denotes HIV that uses the CCR5 chemokine receptor for entry and dual tropic use both X4 and R5
receptors for entry.
b50% effective concentration (EC50) was determined in the TZM-bl indicator cell line from at least three independent assays.
cLate CCR5 HIV-1 virus isolated from PBMC of individuals with AIDS (CDC category IV disease) and CD4 counts ,50 cells/ml.
fNB25 and NB27 are early CCR5 HIV-1 isolated from PBMC of individuals that was asymptomatic with CD4 counts .500 cells/ml (CDC category II disease) or was an acute
seroconvertor with CD4 counts .750 cells/ml (CDC category I disease), respectively [17].
doi:10.1371/journal.pone.0012309.t001
Dendrimer Antiviral Activity
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18.9 mM, n=4) less potent than SPL7013 in inhibiting X4 and
R5 envelope mediated fusion, respectively (Figure 4D). The fusion
inhibitor T-20 (enfurvitide) was included as a positive control and
inhibited both X4 and R5 mediated fusion with FC50 values of
2.060.3 nM and 461 nM, respectively while the NNRTI,
efavirenz did not inhibit cell-to-cell fusion (Figure S3). These data
demonstrate that dendrimers block HIV envelope mediated cell-to-
cell fusion. Notably, the G4 dendrimer is more potent than the
smaller G2 dendrimer in inhibiting R5 envelope-mediated fusion.
Regions of gp120 suitable for interactions with
dendrimers
Our studies demonstrate that SPL7013 and SPL7115 block
HIV-1 entry indicating that they bind to HIV-1 surface proteins
and/or host cell receptors required for entry. In this regard,
previous studies have demonstrated that the anionic polymer,
PRO 2000, harboring naphthalene monosulfonic acid residues,
binds to HIV gp120 in addition to CD4 and the CXCR4
chemokine receptor [28,29]. Moreover, multiple mutations in
HIV-1 gp120 are required to develop resistance to dendrimers as
observed for the related DNAA dendrimer SPL2923 [11,30].
Taken together, these studies indicate that HIV-1 gp120 is one of
the targets of DNAA based dendrimers. To understand how
SPL7115 and SPL7013 bind to gp120 we generated electrostatic
surface views of the dendrimer and the gp120 target as either a
monomer or a trimer (Figure 5). As previously described [31], L-
lysine dendrimers with DNAA caps are predicted to transition
from an elongated structure (G2, SPL7115) to a more compact or
globular structure in later generations (G4, SPL7013). The DNAA
moieties on the dendrimers are predicted to cluster, especially in
earlier generations, resulting in a high density of negative charge
on one face of the G2 and G4 molecules (Figure 5A).
Electrostatic surfaces of the DRNL gp120 monomer (Figure 5B)
and trimer (Figure 5C and D) models were used to examine
possible regions of SPL7115 and SPL7013 binding. In general, the
two faces of the gp120 monomer displayed an even distribution of
positive and negative surface charge suggesting that a polyanionic
dendrimer could interact with a variety of regions of broadly
distributed positive charge (Figure 5B). In contrast, the V3 loops
and regions surrounding the base of the V3 loops were more
densely populated with positively charged residues, the former
being typical of X4 strains of HIV-1. Since the V3 loops vary in
positive charge between X4 and R5 HIV-1 strains, it is likely that
the broad potency observed for SPL7013 and SPL7115 is due in
part to interactions with conserved clusters of positive charge on
gp120. Thus a putative dendrimer binding site on gp120 was
identified that comprises basic residues K121, R325, R417, K419
and K430 that are highly conserved in both X4 and R5 strains
(Figure S4) and are located at the base of the V3 region in the
CD4-induced (CD4i) domain formed by a conformational change
following binding of gp120 to CD4 [32]. The V3 loop in concert
with the CD4i domain form the chemokine coreceptor binding
sites on gp120 [15]. The role of these basic amino acid residues in
dendrimer binding needs to be confirmed by mutagenesis studies.
Comparisons of the relative sizes and surface groups of the
dendrimers (Figure 5A) combined with the gp120 monomers
(Figure 5B) and trimers (Figure 5C and D) highlight that it is
possible to coat the envelope protein with several of the negatively
charged dendrimers (SPL7115 or SPL7013), thereby blocking the
ability of the HIV-1 envelope to fuse with cells.
Discussion
We have shown that dendrimers can be used as a platform to
engineer a diverse array of potent HIV and HSV antivirals, and
have potential for the development as inhibitors of other viral
pathogens. Based on rational design principles and understanding
structure-activity relationships, optimized antiviral dendrimers
were identified. One of these dendrimers, SPL7013, demonstrated
the most potent activity against a broad-spectrum of HIV isolates,
HSV-1 and HSV-2 and is the active pharmaceutical ingredient in
the formulated microbicide, VivaGelH. Mechanism of action
studies demonstrate that SPL7013 blocks entry of both X4 and R5
HIV-1 strains with equal potency and inhibits X4 and R5
envelope mediated cell-to-cell fusion. Modeling studies indicate
the potential for electrostatic interactions of dendrimers with
gp120. The favorable in vivo anti-HSV-2 activity and lack of
toxicity demonstrated in this study along with previously reported
Figure 3. Formulated SPL7013, VivaGelH, protects against HSV-
2 infection and does not increase susceptibility to HSV-2 in the
mouse HSV-2 vaginal transmission model. (A) VivaGelH provides
prolonged protection against HSV-2 infection. VivaGelH (or PBS control)
was delivered vaginally to groups of 10 mice and the viral challenge (10
ID50) was delivered later at the times indicated. The viral inoculum
infected 49 out of 50 control animals. (B) VivaGelH does not increase
susceptibility to HSV-2. Groups of 40 mice were exposed to a single
dose of VivaGelH and HEC placebo gel and after 12 h were challenged
with a low dose (0.1 ID50) HSV-2 inoculum. As previously reported [25],
animals exposed to nonoxynol-9 and several other candidate microbi-
cide detergents become more susceptible to infection for many hours
after exposure reaching a peak at about 12 h after a single exposure.
The increase in susceptibility, as shown by the range bar, indicates the
expected increase in vaginal transmission rate for a low-dose viral
inoculum. In contrast 12 h after exposure to VivaGelH fewer animals
were infected than in PBS control animals.
doi:10.1371/journal.pone.0012309.g003
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explant cultures [33,34], animal safety and efficacy studies [24,35],
and human safety data [36,37] make VivaGelH a promising
microbicide candidate.
Extensive SAR studies were performed to evaluate the optimum
dendrimer size and surface group for HIV-1 inhibitory activity.
The most potent activity against a X4 strain of HIV-1 was
achieved with a dendrimer comprising two generations and
capped with the surface groups, DNAA or 3,5-Ph-(SO3Na)2,
imparting the greatest anionic surface charge and hydrophobicity
of all of the evaluated surface groups. Notably, the anti-HIV
activities of DNAA and 3,5-Ph-(SO3Na)2 capped dendrimers did
not appreciably increase beyond G2 against the NL4.3 strain of
HIV-1. Furthermore, the G4 DNAA dendrimer was only 4-fold
more potent against the R5 HIVBa-L strain compared to the G2
DNAA dendrimer. In contrast, SAR studies for anti-HSV-2
activity revealed a different pattern for DNAA-capped dendrimers
where potency dramatically increased with size as exemplified by a
140-fold increase in potency of the G4 compared to the G2 DNAA
dendrimer. The same pattern with regard to DNAA dendrimer
Figure 4. Mechanism of action studies of SPL7013 and SPL7115. (A) Inhibition of recombinant HIV-1 RT by dendrimers as determined using a
heteropolymeric template-primer in the presence of 0.1 mg/ml BSA and 0.01% IGEPAL to prevent nonspecific binding of dendrimers to the RT. Data
represent the mean of four independent assays. Error bars denote standard error of the mean. (B) Time of addition study performed in the TZM-bl
indicator cell line with 20 and 100 mg/ml of SPL7115 and SPL7013. AMD3100 and nevirapine were included as controls for an entry and HIV-1 RT
inhibitor, respectively. Data is a representative assay from one of three independent assays. (C) Inhibition of R5 and X4 gp120 mediated cell-to-cell
fusion by SPL7013 and (D) SPL7115. Data from fusion assays are the average from at least three independent assays. Error bars denote standard error
of the mean.
doi:10.1371/journal.pone.0012309.g004
Figure 5. Electrostatic surface views of dendrimer and gp120 models. (A) Models of the G2 (SPL7115) and G4 (SPL7013) dendrimers taken
from the last frame of a molecular dynamics simulation [31]. Two views are shown (top and bottom) rotated by 180u around the long axis of the
dendrimer. (B) Two views (rotated by 180u) of the homology model of the DRNL wild-type gp120. CD4 binding site is denoted by a yellow outline and
conserved residues K121, R325, R417, K419 and K430 in the CD4i domain are indicated. (C) Side-view of the DRNL gp120 trimer with the V3 loops
pointing towards the target cell membrane. The space between the gp120 monomers would normally be occupied by gp41. (D) End-on view of the
DRNL gp120 trimer with the V3 loops facing the viewer. Predicted position of gp41 monomers are marked by an asterisk. In all views, the solvent-
accessible surfaces are mapped with regions of negative (red) and positive (blue) electrostatic potential (charge).
doi:10.1371/journal.pone.0012309.g005
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data suggest that dendrimer anionic surface charge in addition to
size is important for HSV inhibition. The larger dendrimers could
lead to steric hindrance between viral and host cell receptor
interactions and play a greater role in HSV compared to HIV
inhibition. Taken together, these studies demonstrate for the first
time that dendrimers can be engineered for optimal inhibition of
HIV-1, HSV-2 and potentially other viral pathogens.
The differences in SAR for HIV-1 and HSV-2 are likely a
consequence of the various targets involved in viral entry.
Productive HIV entry is dependent on gp120 binding to CD4
and chemokine receptors [15,38]. HSV entry relies on viral surface
glycoproteins gB, gC, gD, gH/gL for attachment and fusion with
productive HSV entry dependent on gB and gC binding to
negatively charged heparin sulfate present on cell surface
proteoglycans [39]. This binding promotes subsequent interaction
of gD to one of three classes of surface receptors including herpes
virus entry mediator (HVEM, a member of the TNF receptor
family), nectin 1 and nectin 2 (members of the immunoglobulin
superfamily) ora modified form of heparin sulfate. Interaction ofgD
with its receptors triggers fusion of the viral and cell lipid
membranes which also requires the involvement of gB and the
gH/gL heterodimer [39]. SPL7013 blocks HSV adsorption to cells
[40] and it is possible that this dendrimer interferes with the initial
binding of HSV to heparan sulfate, although this needs to be
confirmed. Thus the ability of dendrimers to interfere with
electrostatic interactions between viral surface proteins and host
cell receptors represents a common mechanism for inhibition of
viral entry,where the potency for a particular virus canbe increased
by the choice of surface group and dendrimer size.
Our studies demonstrate that both SPL7115 and SPL7013 are
HIV entry inhibitors with broad-spectrum anti-HIV activity
against a wide range of X4 and R5 clinical isolates, different
HIV-1 clades, early R5 clinical isolates, HIV-2 and a HIV-1 strain
resistant to reverse transcriptase and protease inhibitors. The
ability of SPL7013 to inhibit early R5 strains isolated from PBMCs
of individuals with an asymptomatic HIV-1 infection (NB25) and
an acute seroconverter (NB27) indicate that SPL7013 is likely to be
active against transmitted/founder strains of HIV-1 that, similar to
early R5 isolates, tend to be more sensitive to inhibition by fusion
inhibitors and chemokine antagonists compared to HIV-1 from
chronically infected individuals [17,41].
Notably, we found that SPL7013 was equally potent in the
inhibition of both X4 and R5 strains of HIV-1. This is in contrast
to what has been described for several linear polyanion-based
microbicide candidates that tend to be more potent inhibitors of
X4 [18,19]. Moreover, a previous study is consistent with our
more extensive findings demonstrating that SPL7013 has similar
potency against HIV-1IIIB (X4 strain) and HIVBa-L (R5 strain) at
both the 50% and 90% inhibitory concentrations [42]. In contrast,
the same study demonstrated that PRO 2000 is more potent
against HIV-1IIIB versus HIVBa-L, particularly at the 90%
inhibitory concentrations [42]. The greater ability of linear
polyanions to inhibit X4 versus R5 strains has been attributed to
their interaction with the highly positively charged V3 loop on
gp120 [18,19,42]. It is likely that SPL7013 also interacts with the
V3 loop of X4 strains. However, its ability to equally block R5
strains in cell culture assays suggests either an interaction with
conserved basic residues in gp120 of both X4 and R5 strains and/
or an ability to bind to host cell receptors required for HIV entry.
In this regard, PRO 2000 binds to gp120, CD4 and chemokine
receptors [28,29,43].
Our evaluation of the anti-HIV-1 activity of SPL7013 in the
presence of high concentrations of human serum and in the
presence of human CVS demonstrate little impact on the ability of
SPL7013 to inhibit HIV-1 in cell culture assays. A previous study
has demonstrated that SPL7013 is active at pH,4.0 (present in
the female genital tract) and that 1 mg/ml of SPL7013
(representing 1/30 SPL7013 levels in VivaGelH) completely
inhibits HIV-1 infection in both viral entry and cell-associated
transmission assays in the presence of human seminal plasma [42].
Furthermore we have demonstrated that VivaGelH recovered after
vaginal dosing in healthy women retained potent antiviral activity
against HIV-1 and HSV-2 in ex vivo assays up to 3 h post-dose in
all participants, where the average SPL7013 recovery was 1/20 of
the original dose. In addition, potent anti-HIV-1 and HSV-2
activity in recovered gel samples up to 3 h post-dose was also
observed in assays performed in the presence of seminal plasma
[44]. Taken together, these findings suggest that SPL7013 is likely
to retain HIV-1 and HSV-2 inhibitory activity in the presence of
CVS and semen during coitus.
Mechanism of action studies demonstrate that while G2 and G4
DNAA dendrimers inhibit recombinant HIV-1 reverse transcrip-
tase, they inhibit HIV-1 entry in cell culture assays. In contrast, a
previous study has shown that SPL2923, a dendrimer with a
different core, PAMAM branches and DNAA surface groups
blocks intracellular HIV-1 reverse transcription in addition to viral
entry [11]. SPL2923 is predicted to have a different shape and
overall surface charge compared to SPL7115 and SPL7013, which
may allow it to enter cells in order to inhibit reverse transcription.
However, differences in the ability of dendrimers to enter TZM-bl
cells used in our study and MT-4 cells used in the study by
Witvrouw and colleagues [11] cannot be excluded. Regardless, the
ability of dendrimers to block HIV entry is likely to represent their
major mechanism of action since their activity for blocking entry is
far more potent than concentrations required to inhibit reverse
transcription in cells [11]. Moreover, an HIV-1 strain with
decreased susceptibility to SPL2923 has been reported that
harbors mutations in gp120 but not in the reverse transcriptase
indicating lack of selective pressure of the dendrimer against the
reverse transcriptase target [11].
Semen harbors both cell-free HIV and HIV infected leukocytes
[45]. However, it is unclear whether the sexual transmission of
HIV is due to cell-free or cell-associated virus or both, although a
recent study suggests the former in men who have sex with men
[46]. To examine the potential of dendrimers to block cell-to-cell
fusion we evaluated the relative capacity of SPL7115 and
SPL7013 to inhibit envelope mediated cell-to-cell fusion. Our
studies demonstrate that G2 and G4 DNAA dendrimers block
envelope mediated cell-to-cell fusion, although SPL7013 was .20-
fold more potent in blocking R5 envelope mediated fusion
compared to SPL7115. These data indicate that dendrimer size
is more important in blocking R5 compared to X4 envelope
mediated fusion. Notably, the CCR5 and CXCR4 antagonists
maraviroc and AMD 3100, respectively failed to inhibit fusion in
this assay (data not shown) suggesting that the multivalency of
dendrimers may be important for inhibiting cell-to-cell fusion. We
also observed that SPL7013 was 12-fold more potent in blocking
R5 compared to X4 envelope mediated fusion. A more modest
difference (,4-fold) was reported for the ability of SPL7013 to
block R5 envelope mediated fusion and R5-tropic cell-associated
HIV-1 transmission compared to assays with X4 envelope and
virus [42]. The different cell types, constructs and expression levels
of CD4, CXCR4 and CCR5 could have accounted for the relative
differences between inhibition of X4 versus R5 envelope mediated
fusion observed in our studies. This is supported by a report
demonstrating that the ability of CCR5 ligands to block HIV
infection is dependent on CCR5 expression levels and other host
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demonstrate that SPL7013 blocks both cell-free and cell-associated
transmission with X4 and R5 HIV strains [42].
We have shown that VivaGelH does not cause toxicity as
measured by an increase in HSV-2 susceptibility when applied to
the vagina of the mouse. These data are consistent with lack of
toxicity found in VivaGelH phase I safety studies in men and women
[36,37] and in vitro studies demonstrating the lack of disruption of
intracellular tight-junctions of polarized epithelial cells by SPL7013
formulated at a higher concentration (5% in Carpobol-based
aqueous gel) compared to VivaGelH used in this study [27].
Disruption of tight junctions and thus the integrity of the epithelial
cell layer in the genital tract by cellulose sulfate (Ushercell) [48] has
been proposed as one of the factors that may have contributed to a
trend towardsincreasedHIV-1acquisitioninwomenusing cellulose
sulfate as a topical microbicide in a randomized, double-blind
placebo controlled phase III trial [20]. It has also been proposed
that enhancement of HIV-1 infection by cellulose sulfate at
threshold antiviral concentrations may have accounted for an
increase in HIV-1 acquisition in vivo [49]. However, enhancement
by cellulose sulfate was not observed using an ex vivo model for HIV-
1 infection comprising human vaginal epithelial sheets containing
CD4+ T lymphocytes and Langherans cells [50]. In addition,
studies in PHA stimulated human PBMCs attributed the marginal
enhancement of HIV-1 replication observed by SPL7013 and PRO
2000toanassayartifactandthereforeisunlikelytoberelevantinvivo
[51]. This notion has been confirmed in two recent efficacy trials,
which did not demonstrate increased HIV acquisition in women
using PRO 2000 [22,52].
Several candidate microbicides from the nonspecific and
moderately specific classes have been evaluated in clinical trials
and either demonstrate no efficacy or promote HIV acquisition in
women [20,21,52,53]. More promisingly, the macromolecular
anionic polymer PRO 2000 formulated as a 0.5% gel reduced
HIV infections by 30% compared to women using placebo gel or
no treatment. While this did not reach statistical significance
(P=0.1), an analysis of women who did not use condoms in this
same study demonstrated that the product provided 80% efficacy
[52]. In marked contrast to the results of this phase IIb PRO 2000
study, a larger phase III trial demonstrated that 0.5% PRO 2000
lacked efficacy in preventing HIV acquisition [22]. Despite the
lack of efficacy demonstrated by linear polyanion based microbi-
cide candidates in preventing the sexual transmission of HIV in
clinical trials, a phase IIb study of a 1% tenofovir gel demonstrated
a statistically significant 39% reduction in HIV infection, proving
the concept of a topical gel-based microbicide for HIV prevention
[54], but leaving room for significant improvement in effect.
The dendrimer, SPL7013, has a chemically defined structure
and a distinct surface group compared to linear polyanion-based
microbicides. SPL7013 also has several advantages over the
ineffective linear polyanions, including an ability to inhibit R5
virus and lack of effect on cellular tight junctions [27]. SPL7013 is
formulated in VivaGelH so that there is ,20,000-fold excess of
dendrimer delivered to the female genital tract compared with the
in vitro EC50 for HIV clinical isolates and ,45,000-fold excess of
dendrimer compared with the in vitro EC50 for a HSV-2 clinical
isolate. Compared to 2 g of 0.5% PRO 2000 [55], VivaGelH (3%
w/w SPL7013 in 3.5 g) delivers 10.5-fold higher levels of active
drug at concentrations that are tolerated in vivo [36]. In contrast
to tenofovir and other similar antiretrovirals, SPL7013 demon-
strates no systemic absorption (and potential toxicity) [9], and
propagation of HIV in cell culture in the presence of SPL7013 for
43 passages results in virus with only a 3-fold decrease in SPL7013
susceptibility compared to wild-type (G. Tachedjian, unpublished
data). In addition, antiretrovirals such as tenofovir need to enter
target cells present in the sub-epithelial layers, thus leaving the
lumen of the female genital tract, where the infection process
commences, potentially unprotected. Finally, a product like
VivaGelH, if effective, would have the advantage of being more
widely available than an antiretroviral drug, which would need a
prescription. Therefore, the continued development of a possible
over-the-counter microbicide is important.
The data presented in the current study provide a clear
rationale and additional supporting data for the development of
the dendrimer SPL7013 and VivaGelH as a broad-spectrum
microbicide with activity against HIV and HSV, and potentially
other sexually transmitted viruses. A future approach that involves
combining a microbicide such as VivaGelH (SPL7013) that
protects the vaginal lumen and has dual action HIV and HSV
inhibitory activity with a specific antiretroviral agent such as
tenofovir, which needs to be delivered to target cells in the sub-
epithelial layers, could potentially provide greater protection
against HIV acquisition than a microbicide with a single active
pharmaceutical ingredient.
Materials and Methods
Ethics Statement
Allexperimentalprotocols inmicewereperformedinaccordance
with the standards established by the US Animal Welfare Acts, set
forth in NIH guidelines and the Policy and Procedures Manual of
Johns Hopkins University Animal Care and Use Committee. The
study protocol MO08M334 ‘‘Evaluating vaginal microbicides in
mice’’, which is specific for the mouse experiments described in this
study, was approved by the Johns Hopkins University Animal Care
and Use Committee (i.e. the Johns Hopkins Animal Ethics
Committee) Chaired by Nancy A. Ator. The Johns Hopkins
University Animal Assurance number is 3272-01.
Dendrimer synthesis and purification
Dendrimer backbone. The preparation of lysine dendri-
mers from the benzhydryl amide protected lysine core and the
subsequent capping reactions have been described previously
[12,13]. The materials were prepared with a high degree of purity
using iterative cycles of Boc deprotection and reaction of the
trifluoroacetic (TFA) salts with excess of the p-nitrophenol active
ester of a,e-
t-Boc2-(L)-lysine. The Boc-protected materials and the
multi-TFA salts are both solids that were further purified through
washing and precipitation steps. All Boc-protected lysine
dendrimers used here (G1–G5) were chemically and physically
stable, and were prepared for subsequent surface functionalisation
as desired.
Surface capping groups. Anionic capping groups were
purchased or synthesized as required. 4-Sulfobenzoic acid sodium
salt (‘‘4-Ph-SO3Na’’) was purchased (Sigma-Aldrich), di-t-butyl-[[(4-
nitrophenyl)oxy]carbonyl]-(L)-glutamate (‘‘glutamic’’) was modified
as described previously [56], 1,3,5-benzenetricarboxylic acid [‘‘3,5-
Ph-(CO2Na)2’’] was purchased (Sigma-Aldrich), 3-sulfo-2-thiophene-
carboxylic acid (‘‘2-thio-3-SO3Na’’) was modified as described
previously [57], 3,5-disulfobenzoic acid disodium salt [‘‘3,5-Ph-
(SO3Na)2’’] was purchased (Sigma-Aldrich), 2-[(3,6-disulfo-1-
naphthalenyl)oxy]-acetic acid disodium salt (‘‘DNAA’’) and 2-[(3-
sulfo-1-naphthalenyl)oxy]-acetic acid (‘‘MNAA’’) were both modified
as described previously [58].
Virus Strains
NL4.3, a X4 strain [59], was derived by transfection of 293T
cells with pDRNL using the calcium phosphate method [60].
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 Virus was propagated at least three times in MT-2 cells prior to
use in anti-HIV assays. HIVBa-L is a R5 laboratory strain, which
was propagated in human PBMCs and macrophages. HIV-1
strains 92RW016 (clade A), 92BR025 (clade C), 92UG046 (clade
D), CMU02 (clade EA), 93BR020 (clade F), BCF01 (clade O) and
HIV-2 were obtained from the NIH AIDS Research and
Reference Reagent Program. HIV-1 clinical isolates CB1-br,
MACS1-spln, MACS3-LN and MAC3-br were isolated from
HIV-1 infected individuals [61] and provided by Dana Gabuzda
(Dana-Farber Cancer Institute). Early circulating (NB25 and
NB27) and late emerging (NB2 and NB6) R5 isolates [17] were
provided by Anthony Cunningham (Westmead Millenium Insti-
tute, Sydney, Australia). Apart from NL4.3 and HIVBa-L all strains
were propagated in PHA-stimulated human PBMCs. HSV-1
strain 250735 and HSV-2 strain 250733 are highly cytopathic
strains isolated from Australian patients that were typed by the
Victorian Infectious Diseases References Laboratory (VIDRL,
Melbourne, Australia) and were provided by Dr Chris Birch [14].
HSV-1 (F) and HSV-2 (G) were obtained from the American Type
Culture Collection.
Cells
MT-2 cells [62] were cultured in RPMI1640 and 10% foetal
calf serum (FCS) buffered with 25 mM HEPES as previously
described [60]. The TZM-bl indicator cell line [63], obtained
through the NIH AIDS Research and Reference Reagent
Program, and 293T cells were cultured in Dulbecco modified
Eagle medium (DMEM) supplemented with 10% FCS, 100 U/ml
penicillin, 100 mg/ml streptomycin and 29.2 mM glutamine
(DMEM-10). Human embryonic lung (HEL) fibroblasts cells were
obtained from VIDRL and were propagated in DMEM-10. PHA-
stimulated human PBMCs from uninfected donors were prepared
as described previously [64]. Cf2-Luc cells [65], derived from the
Cf2th canine thymocyte cell line, stably express the luciferase gene
under the control of the HIV-1 promoter and were cultured in
DMEM-10 supplemented with 0.7 mg/ml of G418.
HIV inhibition assays
Initial screening assays to determine the inhibitory activity of
dendrimers against NL4.3 were performed in the MT-2 T-
lymphocyte cell line using cell viability as the readout as previously
described [66] except that cell viability was determined using the
CellTitre 96 Aqueous One Solution Reagent (Promega) according
to manufacturer’s instructions. Each assay included SPL7013 as a
positivecontrolforHIV-1inhibition withassaysbeingdeemed valid
if the SPL7013 EC50 was within two standard deviations of the
average value of 0.16 mM. The cytotoxicity of dendrimers was
evaluated in parallel,with cultures incubatedinthe absence of virus.
The EC50 and CC50 values were calculated as published [66].
To evaluate the inhibitory activity of the most potent
dendrimers against different HIV-1 clades and clinical isolates,
assays were performed in the TZM-bl indicator cell line that
expresses CD4 and the CCR5 and CXCR4 chemokine receptors
and engineered with the luciferase and b-galactosidase genes
under the control of the HIV-1 promoter [63]. Assays were
performed as published [60] except that luciferase activity was
used to determine HIV replication, which was measured using the
Steady Glo Luciferase Assay System (Promega) according to
manufacturer’s instructions. EC50 values were calculated as
published [60]. Luminescence was measured using a FLUOStar
Optima microplate reader (BMG LABTECH, GmbH, Germany).
SPL7013 inhibition of HIV-1 in human peripheral blood
mononuclear cells and in the presence of human serum and
cervicovaginal secretions in TZM-bl cells were performed as
described in Supplementary Methods S1.
HSV inhibition assays
The anti-HSV-1 and -HSV-2 activities of dendrimers were
determined in HEL cells using cell viability as the readout for viral
replication. HEL cells were seeded at 6,000 cells per well of a 96
well plate in DMEM-10 and incubated overnight at 37uCi n5 %
CO2. Following incubation, medium was removed and cells
replenished with DMEM supplemented with 2% FCS (DMEM-2)
containing dendrimer at twice the final concentration and infected
with 500 TCID50 of HSV. Cells were incubated for 4–6 days at
37uCi n5 %C O 2 until cytopathic effects were observed in 100% of
the cells in cultures containing virus without drug. After
incubation, the medium was removed and cells were replenished
with 100 ml of DMEM containing 2% FCS after which the cell
viability was determined using the CellTiter 96 Aqueous One
Solution Reagent (Promega) according to manufacturer’s instruc-
tions. The dendrimer EC50 values were calculated from three
independent assays as described previously [66]. The EC50 value
obtained for SPL7013 in our assay was similar to the value
obtained using a plaque reduction assay for HSV [24].
Mouse model for evaluating protection and susceptibility
to HSV-2
The methods for both the protection test and susceptibility test
for toxic effects were as previously described [25]. Briefly, female
CF-1 mice 6–8 weeks old (Harlan, Indianapolis, IN) were injected
subcutaneously with 2.5 mg Depo-ProveraH (medroxyprogester-
one acetate, Pharmacia & Upjohn Company, Kalamazoo, MI), a
treatment that synchronizes the mice into a diestrous-like state that
exposes living cells on the entire surface of the vagina, greatly
increases HSV-2 susceptibility, and makes mice uniformly
susceptible to HSV-2. Strain G of HSV-2 (ATCC lot
#3405329)(Virotech International, Rockville, MD) was diluted
with Bartels Tissue Culture Refeeding Medium (Trinity Biotech,
St Louis, MO) and the viral inoculum delivered with a Wiretrol
pipet (Drummond Scientific, Broomall, PA) with a fire polished tip
to minimize potential injury.
For the HSV-2 protection test, 20 ml of VivaGelH (or PBS) was
delivered to the vagina and the 10 ml viral inoculum containing 10
ID50 (,10
4 TCID50) was delivered after a specified time interval.
For each time point 10 mice received VivaGelH and 10 controls
received PBS.
For the HSV-2 susceptibility test, 20 ml of VivaGelH (or HEC
placebo gel) was delivered to the vagina, and then a low dose
inoculum with 0.1 ID50 was delivered in 10 ml of Bartels medium
12 h later, a time interval at which prior tests indicate the greatest
increase in susceptibility is likely to occur. To determine the
relative susceptibility of the mice, a dose-response curve was
obtained to observe the fraction of mice infected as a function of
the viral dose delivered. The dose-response curve was used to
determine the effective ID of the low-dose inoculum in the test
animals. Relative susceptibility is defined as the ratio of the
effective ID the low-dose inoculum delivered to the test mice
divided by the ID it delivered to control animals. A total of 40
mice received VivaGelH and 40 mice received HEC placebo.
For both the HSV-2 protection and susceptibility tests, vaginal
lavages were obtained 3 days after inoculation and evaluated for
viral shedding. Bartels Medium (50 ml) was delivered to the vagina
and pipetted in and out 20 times to maximize viral recovery, then
diluted into 50 ml Bartels Medium. The vaginal lavage was
clarified by centrifugation (6,500 rpm, 5 min) and the supernatant
was placed on human newborn foreskin diploid fibroblast target
Dendrimer Antiviral Activity
PLoS ONE | www.plosone.org 12 August 2010 | Volume 5 | Issue 8 | e12309cells (Biowhitaker, Walkersville, MD). Cytopathic effect was scored
48 h later and mice whose lavage cultures displayed cytopathic
effects were considered infected.
Inhibition of recombinant HIV-1 RT
HIV-1 RT was expressed from pRT6H-PROT and purified as
previously described [60]. Assays were performed by pre-
incubating 25 ng of HIV-1 RT with the test compound in
50 mM Tris-HCl, pH 7.8, 0.1 mg/ml bovine serum albumin
(BSA) and 0.01% IGEPAL for 30 min on ice. The reaction
was initiated by adding 200 nM of a 35-nucleotide DNA tem-
plate [(59-AGAATGGAAAATCTCTAGCAGTGGCGCCCGA
ACAG-39) annealed to a 26-nucleotide DNA primer (59-
CCTGTTCGGGGCCACCTGCTAGAGAT-39)], 10 mMo fa
dNTP mixture and 5 mCi of
33PdTTP (Perkin Elmer) in 50 mM
Tris-HCl, pH 7.8, 60 mM KCl, 2 mM dithiothreitol, 5 mM
MgCl2, 0.1 mg/ml BSA, 0.01% IGEPAL for 1 h at 37uC.
Following incubation, samples were applied to DE81 membrane,
washed and incorporated counts quantified using a FLA-2000
phosphorimager (Fujifilm).
Time of addition assay
TZM-bl cells were seeded in 96-well tissue culture plates at
2.5610
4 cells per well in 100 ml of DMEM-10. Cells were grown
for 12 h at 37uCi n5 %C O 2 after which triplicate wells were
infected with NL4.3 at a multiplicity of infection of one by
spinoculation. Briefly, DMEM-10 was removed from cells and
replaced with 100 ml of virus in DMEM-10 and plates were
centrifuged at 1200 g for 60 min at 17uC. Viral inoculum was
removed and cells washed twice with 250 ml of cold DMEM-10
after which 100 ml of DMEM-10 or DMEM-10 containing drug
was added at t=0 to appropriate cells. DMEM-10 containing
drug was subsequently added at t=2, 3, 4, 5, 6, 8 and 24 h post
infection to appropriate wells. At 31 h postinfection, HIV-1
replication was determined by measuring luciferase activity as
above.
Cell-to-Cell Fusion assays
The gp120 gene from the R5 HIV-1 strain ADA and X4 HIV-1
strain HXB2 was cloned into a HIV-1 Env expression vector.
Briefly, the 2.1 kb HIV-1 env within Kpn I and Bam HI restriction
sites was cloned from viral genomic DNA into pSVIII-HXB2 Env
expression vector [67]. The pcDNA3-CD4, pcDNA3-CCR5 and
pcDNA3-CXCR4 plasmids express human CD4, R5 and X4
respectively [61]. pSVTat expresses the HIV-1 Tat protein. Cell-
cell fusion assays were conducted as described previously [68].
Briefly, Cf2-Luc target cells seeded in 25 cm
2 tissue culture flasks
were transfected with 1 mg of CD4 plasmid and 3 mgo fR 5o rX 4
plasmid. 293T effector cells seeded in 6-well tissue culture plates
were co-transfected with 3.4 mg of ADA or HXB2 gp120-
expressing plasmid and 0.6 mg pSVTat. Target and effector cells
were transfected using Lipofectamine 2000 (Invitrogen) according
to the manufacturers’ protocol. Effector cells expressing ADA or
HXB2 Env were pre-incubated in DMEM-10 containing 10-fold
increasing concentrations of efavarenz, T-20, dendrimer or no
drug (untreated controls) for 30 min at 37uC. Approximately
2610
4 effector cells were added to 2610
4 Cf2-Luc target cells and
were incubated at 37uC in replicate wells containing 200 mlo f
culture. Cells from replicate wells were harvested at 7 h post-
mixing and assayed for luciferase activity (Promega) according to
the manufacturers’ protocol. 293T cells transfected with pSVTat
alone were used as negative controls to determine the background
level of luciferase activity.
Generation and computational analysis of dendrimer and
gp120 models
Coordinates for the dendrimer models were taken from the last
frames of a molecular dynamics simulation [31]. The crystal
structure of JRFL gp120 containing the V3 variable loop and
bound to CD4 and the X5 Fab antibody fragment was used as the
template for CD4-bound model of the DRNL wild-type gp120
protein (Protein Data Bank ID: 2B4C) [69]. Trimeric gp120
homology models were generated using the coordinates of the
gp120/CD4/17b crystal structure that had been fitted to a cryo-
electron tomography structure of the HIV-1 Env spike (Protein
Data Bank ID: 3DNO) [70]. Solvent-accessible surfaces were
generated in DS Visualizer version 2.0 (Accelrys, USA) using a
probe radius of 1.7 A ˚. Electrostatic surface potential was
calculated by assigning partial charges to all heavy atoms and
applying a distance cut-off of 12.5 A ˚ for mapping charges (red for
negative and blue for positive) to the molecular surfaces.
Statistical analysis
The statistical significance of differences between EC50 and
FC50 values obtained from cell culture drug susceptibility and
fusion assays were determined using the Wilcoxon rank-sum test.
Fisher’s exact two-sided test was used to analyze numbers of mice
infected and uninfected in test groups vs control groups in the
protective efficacy assay.
Supporting Information
Methods S1 Supplementary Materials and Methods.
Found at: doi:10.1371/journal.pone.0012309.s001 (0.05 MB
DOC)
Figure S1 Selectivity of L-lysine against the NL4.3 strain of
HIV-1 in MT-2 cells. G1–G5 represent generation 1 to generation
5 dendrimers.
Found at: doi:10.1371/journal.pone.0012309.s002 (2.66 MB TIF)
Figure S2 HIV-1 inhibitory activity of SPL7013 in the absence
and presence of 40% human serum (HS)(A) or different dilutions
of human cervical vaginal secretions (CVS)(B). Experiments were
performed in the TZM-bl indicator cell line using luciferase as the
measure of HIV-1 replication. Fig. S2(A) is representative data
from one of two independent assays. Data in Fig. S2(B) were from
three independent assays. EC50 denotes 50% effective concentra-
tion and SE, standard error.
Found at: doi:10.1371/journal.pone.0012309.s003 (0.30 MB TIF)
Figure S3 Inhibition of CCR5 and CXCR4 gp120 mediated
cell-to-cell fusion by T-20 (enfuvirtide)(A) and efavirenz (B). Data
are the average of at least three independent assays. Error bars
denote standard error of the mean.
Found at: doi:10.1371/journal.pone.0012309.s004 (0.23 MB TIF)
Figure S4 Sequence alignment of gp120 proteins derived from
HIV-1 and HIV-2 isolates showing conserved basic residues. The
b-2 (A) and b-3 (B) strands of the bridging sheet, V3 loop (C), b-20
(D) and b-21 (E) stands of the bridging sheet are shown. Amino
acid sequence is colored according to polarity: Polar, green; Non-
polar, black; Positively-charged, blue: Negatively charged, red.
Numbered according to NL4.3.
Found at: doi:10.1371/journal.pone.0012309.s005 (10.98 MB
TIF)
Table S1 Activity of potent dendrimers against the CCR5 strain
HIVBaL.
Found at: doi:10.1371/journal.pone.0012309.s006 (0.06 MB
DOC)
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PLoS ONE | www.plosone.org 13 August 2010 | Volume 5 | Issue 8 | e12309Table S2 SPL7013 has broad-spectrum activity against HIV-1
strains in human PBMC.
Found at: doi:10.1371/journal.pone.0012309.s007 (0.07 MB
DOC)
Table S3 SPL7013 is active against HIV-2 in PBMCs.
Found at: doi:10.1371/journal.pone.0012309.s008 (0.05 MB
DOC)
Table S4 SPL7013 is active against a multi-drug resistant HIV-1
strain in PBMCs.
Found at: doi:10.1371/journal.pone.0012309.s009 (0.04 MB
DOC)
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